'); /* Uncomment for mobile button that says 'MENU' $('.custom-menu-primary .hs-menu-wrapper').before('
MENU
'); */ $('.custom-menu-primary .flyouts .hs-item-has-children > a').after('
'); $('.mobile-trigger').click(function() { $(this).next('.custom-menu-primary .hs-menu-wrapper').slideToggle(250); $('body').toggleClass('mobile-open'); $('.child-trigger').removeClass('child-open'); $('.hs-menu-children-wrapper').slideUp(250); return false; }); $('.child-trigger').click(function() { $(this).parent().siblings('.hs-item-has-children').find('.child-trigger').removeClass('child-open'); $(this).parent().siblings('.hs-item-has-children').find('.hs-menu-children-wrapper').slideUp(250); $(this).next('.hs-menu-children-wrapper').slideToggle(250); $(this).next('.hs-menu-children-wrapper').children('.hs-item-has-children').find('.hs-menu-children-wrapper').slideUp(250); $(this).next('.hs-menu-children-wrapper').children('.hs-item-has-children').find('.child-trigger').removeClass('child-open'); $(this).toggleClass('child-open'); return false; }); });

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.
Medius Associates

Written By
Medius Associates

Medius Deal Watch November 2017

Medius Associates Deals Watch

11 December 2017

Medius Deal Watch November 2017

For some time now, Medius has noted that corporate acquisitions are in decline. And this month’s statistics bear that out – only one company acquisition was announced; that of Ocera Therapeutics by Mallincrodt. All the other five purchases in the top 20 were partial acquisitions, with buyers acquiring a division of a company or making a minority investment. Even the acquisition of the Stelic Institute by Mitsubishi Tanabe was preceded by Stelic splitting itself into two parts, with Mitsubishi Tanabe acquiring the gastro-intestinal assets alone.

 

Licensor/Acquisition Target
Licensee/Acquirer		 Deal Type Headline ($m)

Loxo Oncology

Bayer

 Licence to develop and commercialise 1,550

ZymeWorks

Johnson & Johnson

 Licence to research, develop, and commercialise 1,452

PeptiDream

Bayer AG

 Drug discovery collaboration 1,110

Principia Biopharma

Sanofi

 Licence 805

Halyard Health

Owens & Minor

 Acquisition of division 710
Click here to view the top 20 deals for November 2017

 

The full report also contains:

  • The harsh reality of liver disease
  • The cost of not doing a deal
  • Platform deals
  • High scoring teams from big pharma

Want to read the complete report?

DOWNLOAD THE DEAL WATCH NOVEMBER 2017

Interested in reading the past issues? 

  • Download the Deal Watch October 2017 HERE
  • Download the Deal Watch September 2017 HERE
  • Download the Deal Watch August 2017 HERE
  • Download the Deal Watch July 2017 HERE
  • Download the Deal Watch May 2017 HERE
  • Download the Deal Watch April 2017 HERE
  • Download the Deal Watch March 2017 HERE
  • Download the Deal Watch February 2017 HERE
  • Download the Deal Watch January 2017 HERE
  • Download the 2016 annual review HERE
Medius Associates
Written By

Add Your Response

ABOUT THE BLOG

The Drugs & Dealers Blog provides genuine thought leadership, exclusive executive insight and market intelligence on the life science and healthcare investment sector.

DEALS WATCH

In partnership with Medius Associates

Medius' monthly review of the top deals by value in the healthcare sector

 
VIEW MORE

CATEGORIES

see all

Subscribe Email

UPCOMING CONFERENCE
5-6 February 2018,
World Congress

Connecting Europe's Life Science corporates with capital. 
LEARN MORE
ABOUT US

Biotech and Money is the influential community of senior life science decision makers
SITE MAP
HELP

© 2016 All Rights Reserved By Biotech and Money
Top Arrow